Circulation, Volume 150, Issue Suppl_1, Page A4145478-A4145478, November 12, 2024. Introduction:Pericarditis is an inflammation of the pericardium, a thin sac-like membrane surrounding the heart, which can progress to life threatening cardiac tamponade. It can be caused by infections (viral, bacterial, fungal, or parasitic), autoimmune conditions, injuries, or underlying medical conditions. Common symptoms include chest pain, fever, shortness of breath, and fatigue. In the case presented, the patient suffered from a severe form of pericarditis caused by a rare infectious etiology, leading to the development of cardiac tamponade.Case Summary:A 29-year-old female with type II diabetes and hypothyroidism presented with a week of shortness of breath, chest pain, lightheadedness, and loss of consciousness. Workup showed WBC (20.6), CRP (283), and ESR (85). Echocardiogram revealed a large pericardial effusion with right ventricular collapse, indicating cardiac tamponade. She underwent pericardiocentesis, draining 400 ml of exudative fluid. Unfortunately, the effusion rapidly re-accumulated, requiring a pericardial window procedure with drainage of fibrinous, loculated fluid over 2 days, improving her symptoms. She was discharged on colchicine and NSAIDs, however she returned 5 days later with recurrent symptoms and fever. The culture of the previous fluid showed Cutibacterium acne. Histopathology of pericardial biopsy revealed fibrinoid pericarditis. She was treated with ceftriaxone, and transitioned to doxycycline for 14 days, along with 14 days of ibuprofen and 3 months of colchicine. At 3-month follow-up, she was asymptomatic with no effusion recurrence.Conclusion::As bacterial pericarditis cases rise, the initial work-up should include investigating bacterial etiology. This raises the question of antibiotic coverage for patients presenting with pericardial effusion until bacterial etiology is excluded and also advocate for elective pericardiocentesis in bacterial effusions without tamponade physiology.
Risultati per: Acne vulgaris: trattamento farmacologico
Questo è quello che abbiamo trovato per te
Read More →
Novembre 2024
Linea guida per la terapia del sovrappeso e dell’obesità resistenti al trattamento comportamentale nella popolazione adulta con comorbilità metaboliche
Read More →
2023
Linee guida ESC/ERS 2022 per la diagnosi e il trattamento dell’ipertensione polmonare
Read More →
Ottobre 2022
Farmaci utilizzabili per il trattamento della malattia COVID-19
Read More →
Marzo 2023
Trattamento e prevenzione della cachessia neoplastica
Read More →
Ottobre 2024
Position paper della French Headache Society sul trattamento dell’emicrania
Read More →
Ottobre 2024
Acne Fulminans
New England Journal of Medicine, Volume 391, Issue 15, Page 1440-1440, October 17, 2024.
Read More →
Ottobre 2024
Nuova opzione di trattamento per la sclerosi multipla
Read More →
Ottobre 2024
Fibrosi polmonare, Nerandomilast potenziale trattamento orale
Bene lo studio di fase III
Read More →
Settembre 2024
Scambia, 'per il tumore di Bianca Balti ottime possibilità di trattamento'
‘In molti casi otteniamo la guarigione, ma la prevenzione è fondamentale’
Read More →
Settembre 2024
ACG: linee guida sul trattamento dell’infezione da Helicobacter pylori
Read More →
Settembre 2024
Linee guida ESC 2024 per la prevenzione e il trattamento dell’ipertensione arteriosa
Read More →
Settembre 2024
Strategia generale per il trattamento dei pazienti con ipertensione
Read More →
Agosto 2024
Determinato il momento ottimale per il trattamento del cancro
Read More →
26 Agosto 2024
Linee guida per il trattamento dell’emofilia congenita A e B
Read More →
Agosto 2024
Calcitonin Gene-Related Peptide Inhibition and Development of Acne and Rosacea
This cohort study investigates whether calcitonin gene-related peptide inhibition is associated with reduced rates of developing acne or rosacea in patients who experience migraines.
Read More →
Agosto 2024